Group 1 - Hainan Airlines (600221) focuses on international, domestic, and regional air passenger and cargo transportation, operating nearly 1800 routes and covering all provinces in China, as well as over 100 international routes [1][30] - Hainan Airport (600515) operates major airports in Hainan and is involved in airport construction, management, and related industries, including aircraft maintenance and logistics [2][31] - Zhongtung High-tech (000657) is a state-owned enterprise focusing on the tungsten and hard alloy industry, with a complete industrial chain from tungsten ore to products, and is involved in high-end manufacturing sectors [3][32] Group 2 - Jinpan Technology (688676) is a key player in the new energy sector, specializing in the research and manufacturing of power distribution and control equipment, benefiting from supportive policies in Hainan [4][33] - Haixia Co., Ltd. (002320) controls important maritime transport routes, enhancing its passenger and cargo transport services, and is positioned to benefit from increased demand post-border closure [5][34] - Hainan Mining (601969) focuses on mineral resource extraction and processing, with products supporting the new energy battery industry, and is exploring green development models [6][35] Group 3 - Hainan Rubber (601118) is a leading enterprise in natural rubber production, extending its business into rubber products and international trade, leveraging Hainan's free trade policies [7][36] - Guangsheng Nonferrous (600259) specializes in non-ferrous metal mining and smelting, with a focus on rare earths and tungsten, essential for high-end manufacturing and new energy sectors [8][37] - Haima Automobile (000572) is transitioning into the new energy vehicle sector, supported by Hainan's policies, and is expanding its production capabilities [9][38] Group 4 - Haide Co., Ltd. (000567) focuses on distressed asset management, with a strategy to optimize asset allocation in the region, and is involved in photovoltaic projects [10][39] - Hainan Public Transport Group (603069) provides passenger transport services and is enhancing its operations through the integration of duty-free services [11][40] - Junda Co., Ltd. (002865) is engaged in the new energy sector, focusing on photovoltaic battery research and manufacturing, and is expanding its market presence [12][41] Group 5 - Luoniushan (000735) is involved in livestock farming and related industries, leveraging Hainan's agricultural resources to expand its market [13][42] - Jingliang Holdings (000505) focuses on oil processing and food manufacturing, utilizing Hainan's logistics advantages for trade [14][43] - Hainan Coconut Island (600238) specializes in alcoholic beverages, particularly health wines, and is expanding its market through tourism channels [15][44] Group 6 - Hainan Haiyao (000566) is a pharmaceutical manufacturer focusing on chemical raw materials and traditional Chinese medicine, benefiting from supportive policies for the pharmaceutical industry [16][45] - Hainan Ruize (002596) produces construction materials and is involved in tourism, aligning its business with Hainan's infrastructure development [17][46] - Hainan Expressway (000886) operates key highways in Hainan and is expanding its business through tourism and duty-free services [18][47] Group 7 - Puli Pharmaceutical (300630) specializes in chemical drug development and international market expansion, leveraging Hainan's trade policies [19][48] - Shennong Technology (300189) focuses on seed research and production, aiming to expand its market through trade policies [20][49] - Shuangcheng Pharmaceutical (002693) is dedicated to peptide drug development and international market expansion, supported by Hainan's policies [21][50] Group 8 - Xinlong Holdings (000955) specializes in non-woven fabrics and related products, with a focus on medical and industrial applications, and is exploring export opportunities [22][51] - ST Intercontinental (600759) is involved in oil and gas exploration and is expanding into the hydrogen energy sector [23][52] - Huawen Group (000793) operates in media, tourism, and supply chain services, aiming for growth through Hainan's logistics advantages [24][53]

（文章来源：证券日报） 证券日报网讯 12月24日，灵康药业发布公告称，公司2025年第三次临时股东会审议通过《关于聘任 2025年度审计机构的议案》。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603669 证券简称：灵康药业 公告编号：2025-078 灵康药业集团股份有限公司 2025年第三次临时股东会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 二、 议案审议情况 审议结果：通过 | 1、出席会议的股东和代理人人数 | 212 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 311,458,143 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 44.2699 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，由公司董事长陶灵萍女士主持。本次会议的召 (一) 股东会召开的时间：2025 年 12 月 24 日 (二) 股东会召开的地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵康药业有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持 ...

上海东方华银律师事务所 法律意见书 上海东方华银律师事务所 关于灵康药业集团股份有限公司 2025 年第三次临时股东会 之 法律意见书 上海东方华银律师事务所 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 上海东方华银律师事务所 法律意见书 2025 年第三次临时股东会之法律意见书 致：灵康药业集团股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受灵康药业集团股份有限 公司（以下简称"贵司"或"公司"）委托，就贵司召开 2025 年第三次临时股 东会的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、《上 市公司股东会规则》（以下简称《股东会规则》）等法律、法规和其他规范性文 件以及《灵康药业集团股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东会的相关资料， 包括但不限于公司召开 2025 年第三次临时股东会的通知、公司 2025 年第三次临 时股东会的议程、议案及决议等文件资料，同时听取了公司董事会秘书就有关事 实的陈述和说明。公司已向本所作出保证和承诺，保证公司向 ...

灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料 (603669) 二〇二五年十二月 灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料 灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料目录 | 2025 | 年第三次临时股东会会议议程 2 | | --- | --- | | 2025 | 年第三次临时股东会会议须知 4 | | 议案一：关于聘任 | 2025 年度审计机构的议案 5 | 第 1 页 共 7 页 灵康药业集团股份有限公司 2025 年第三次临时股东会会议资料 灵康药业集团股份有限公司 2025 年第三次临时股东会会议议程 现场会议时间：2025 年 12 月 24 日 14 点 30 分 现场会议地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵 康药业有限公司会议室 议程： 一、 签到、宣布会议开始 1、与会人员签到，领取会议资料；股东及股东代理人同时提交身份证明材 料（授权委托书、营业执照复印件、身份证复印件等）并领取《表决票》； 五、等待网络投票结果 第 2 页 共 7 页 召集人：公司董事会 主持人：董事长陶灵萍 2、主持人 ...

Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. has decided not to exercise the downward adjustment of the conversion price for its convertible bonds, despite triggering the conditions for such an adjustment due to stock price performance [2][5][6]. Group 1: Convertible Bond Details - The company issued 5.25 million convertible bonds on December 1, 2020, with a total amount of 525 million yuan and a maturity of 6 years [3]. - The initial conversion price was set at 8.81 yuan per share, which has been adjusted multiple times, with the latest price being 6.50 yuan per share [3][4]. - The conversion period for the bonds is from June 7, 2021, to November 30, 2026 [6]. Group 2: Price Adjustment Conditions - As of December 9, 2025, the stock price has been below 85% of the current conversion price for at least 15 trading days within a 30-day period, triggering the price adjustment clause [2][5]. - The board of directors has decided not to propose a downward adjustment for the conversion price, considering various factors including the company's fundamentals and market conditions [5][6]. - If the conditions for downward adjustment are triggered again within the next month, the company will still not propose an adjustment, and the board will reassess the situation starting January 12, 2026 [2][6].

Core Viewpoint - Lingkang Pharmaceutical announced that its stock price has fallen below 85% of the current conversion price for at least 15 trading days within a consecutive 30-day period, triggering the downward adjustment clause for its convertible bonds [2] Group 1: Company Actions - The company's board of directors has decided not to exercise the right to adjust the conversion price of the "Lingkang Convertible Bonds" downward at this time [2] - The company will not propose a downward adjustment plan if the conditions for the conversion price adjustment are triggered again within the next month, from December 10, 2025, to January 9, 2026 [2] - Starting from January 12, 2026, if the conditions for the downward adjustment are triggered again, the board will convene to review whether to exercise the right to adjust the conversion price [2]

灵康药业集团股份有限公司 关于不向下修正"灵康转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： | 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2025-077 | | --- | --- | --- | | 证券代码：113610 | 证券简称：灵康转债 | | 2、因公司实施 2021 年年度利润分配方案，自 2022 年 7 月 5 日起，转股价 格调整为 8.51 元/股，具体内容详见《关于权益分派引起的"灵康转债"转股价 格调整的公告》（公告编号：2022-042）。 3、因触发"灵康转债"转股价格修正条款，自 2024 年 7 月 16 日起，转股 价格由 8.51 元/股修正为 8.00 元/股，具体内容详见《关于向下修正"灵康转债" 转股价格暨转股停复牌的公告》（公告编号：2024-053）。 4、因触发"灵康转债"转股价格修正条款，自 2025 年 8 月 1 日起，转股价 格由 8.00 元/股修正为 6.50 元/股，具体内容详见《关于向下修正" ...

Group 1 - The company plans to appoint Zhongshen Yatai Accounting Firm as the auditor for the 2025 fiscal year, replacing the previous auditor Zhongshen Zhonghuan [2][11] - The change in auditing firms is aimed at ensuring the smooth progress of the annual audit work, considering the company's business situation and actual needs [2][11] - The previous auditor has no objections to the change, and the company has communicated thoroughly with both the former and new auditors [11][12] Group 2 - Zhongshen Yatai Accounting Firm was established on January 18, 2013, and operates as a special general partnership [3] - The firm has 93 partners and 482 registered accountants, with over 180 accountants having signed audit reports for securities services [3][4] - The firm's total audited revenue for the last year was approximately 703.98 million yuan, with audit business revenue of about 682.03 million yuan [4] Group 3 - The audit fee for 2025 is set at 850,000 yuan, which remains unchanged from the previous year [10] - The company has conducted a thorough review of the auditor's qualifications, professional competence, investor protection capabilities, integrity, and independence before making the appointment [11][12] - The board of directors approved the appointment of the new auditor with a unanimous vote of 7 in favor and no objections [12][36] Group 4 - The company will hold its third extraordinary general meeting on December 24, 2025, to discuss the appointment of the new auditor [15][16] - The meeting will utilize a combination of on-site and online voting methods, with specific timeframes for voting [17][21] - Shareholders must register to attend the meeting, with detailed requirements for both corporate and individual shareholders [23][26]

Core Viewpoint - Lingkang Pharmaceutical announced that its stock price has been below 85% of the current conversion price for 10 trading days, indicating a potential trigger for downward adjustment of the conversion price as per the prospectus [2] Group 1 - The stock price has been below the conversion price of 5.53 yuan per share for the specified period [2] - The company will convene a board meeting on the triggering date to decide whether to adjust the conversion price and will fulfill its information disclosure obligations promptly [2]